Anemia is a common finding in patients with heart failure (HF). The cause for anemia is multifactorial, with iron deficiency being the most common cause. Anemia with HF is an established predictor of morbidity and mortality. Iron deficiency in systolic HF, even without anemia, has been associated with increased mortality, increased hospitalizations, and decreased functional capacity and quality of life measures. Data from several randomized controlled trials and meta-analyses of iron deficiency and systolic HF show a beneficial effect for intravenous (IV) iron in terms of quality of life and functional capacity (improvements in 6-min walk test, and improvements in New York Heart Association functional class), as well as decreased hospitalizations for HF and reduction in cardiovascular mortality rates. Limited evidence exists for a beneficial effect of IV iron in diastolic dysfunction. Patients with symptomatic systolic HF should undergo an anemia diagnostic work-up. When iron deficiency (defined as ferritin <100 ng/mL or serum ferritin 100–299 ng/mL and transferrin saturation <20%) is present, current evidence supports treating HF patients with iron deficiency with IV iron.

1.
Felker
GM
,
Adams
KF
 Jr
,
Gattis
WA
,
O’Connor
CM
.
Anemia as a risk factor and therapeutic target in heart failure
.
J Am Coll Cardiol
.
2004
Sep
;
44
(
5
):
959
66
.
[PubMed]
0735-1097
2.
Wexler
D
,
Silverberg
D
,
Sheps
D
,
Blum
M
,
Keren
G
,
Iaina
A
, et al.
Prevalence of anemia in patients admitted to hospital with a primary diagnosis of congestive heart failure
.
Int J Cardiol
.
2004
Jul
;
96
(
1
):
79
87
.
[PubMed]
0167-5273
3.
Anand
IS
,
Kuskowski
MA
,
Rector
TS
,
Florea
VG
,
Glazer
RD
,
Hester
A
, et al.
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT
.
Circulation
.
2005
Aug
;
112
(
8
):
1121
7
.
[PubMed]
0009-7322
4.
Al-Ahmad
A
,
Rand
WM
,
Manjunath
G
,
Konstam
MA
,
Salem
DN
,
Levey
AS
, et al.
Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction
.
J Am Coll Cardiol
.
2001
Oct
;
38
(
4
):
955
62
.
[PubMed]
0735-1097
5.
Silverberg
DS
,
Wexler
D
,
Blum
M
,
Keren
G
,
Sheps
D
,
Leibovitch
E
, et al.
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
.
J Am Coll Cardiol
.
2000
Jun
;
35
(
7
):
1737
44
.
[PubMed]
0735-1097
6.
Opasich
C
,
Cazzola
M
,
Scelsi
L
,
De Feo
S
,
Bosimini
E
,
Lagioia
R
, et al.
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure
.
Eur Heart J
.
2005
Nov
;
26
(
21
):
2232
7
.
[PubMed]
0195-668X
7.
Nanas
JN
,
Matsouka
C
,
Karageorgopoulos
D
,
Leonti
A
,
Tsolakis
E
,
Drakos
SG
, et al.
Etiology of anemia in patients with advanced heart failure
.
J Am Coll Cardiol
.
2006
Dec
;
48
(
12
):
2485
9
.
[PubMed]
0735-1097
8.
Auerbach
M
,
Adamson
JW
.
How we diagnose and treat iron deficiency anemia
.
Am J Hematol
.
2016
Jan
;
91
(
1
):
31
8
.
[PubMed]
0361-8609
9.
Jankowska
EA
,
von Haehling
S
,
Anker
SD
,
Macdougall
IC
,
Ponikowski
P
.
Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives
.
Eur Heart J
.
2013
Mar
;
34
(
11
):
816
29
.
[PubMed]
0195-668X
10.
Nemeth
E
,
Tuttle
MS
,
Powelson
J
,
Vaughn
MB
,
Donovan
A
,
Ward
DM
, et al.
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization
.
Science
.
2004
Dec
;
306
(
5704
):
2090
3
.
[PubMed]
0036-8075
11.
Groenveld
HF
,
Januzzi
JL
,
Damman
K
,
van Wijngaarden
J
,
Hillege
HL
,
van Veldhuisen
DJ
, et al.
Anemia and mortality in heart failure patients a systematic review and meta-analysis
.
J Am Coll Cardiol
.
2008
Sep
;
52
(
10
):
818
27
.
[PubMed]
0735-1097
12.
Ezekowitz
JA
,
McAlister
FA
,
Armstrong
PW
.
Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure
.
Circulation
.
2003
Jan
;
107
(
2
):
223
5
.
[PubMed]
0009-7322
13.
Jankowska
EA
,
Rozentryt
P
,
Witkowska
A
,
Nowak
J
,
Hartmann
O
,
Ponikowska
B
, et al.
Iron deficiency: an ominous sign in patients with systolic chronic heart failure
.
Eur Heart J
.
2010
Aug
;
31
(
15
):
1872
80
.
[PubMed]
0195-668X
14.
Haas
JD
,
Brownlie
T
 4th
.
Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship
.
J Nutr
.
2001
Feb
;
131
(
2
2S-2
):
676S
88S
.
[PubMed]
0022-3166
15.
Enjuanes
C
,
Bruguera
J
,
Grau
M
,
Cladellas
M
,
Gonzalez
G
,
Meroño
O
, et al.
Iron Status in Chronic Heart Failure: Impact on Symptoms, Functional Class and Submaximal Exercise Capacity
.
Rev Esp Cardiol (Engl Ed)
.
2016
Mar
;
69
(
3
):
247
55
.
[PubMed]
1885-5857
16.
Toblli
JE
,
Lombraña
A
,
Duarte
P
,
Di Gennaro
F
.
Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency
.
J Am Coll Cardiol
.
2007
Oct
;
50
(
17
):
1657
65
.
[PubMed]
0735-1097
17.
Enjuanes
C
,
Klip
IT
,
Bruguera
J
,
Cladellas
M
,
Ponikowski
P
,
Banasiak
W
, et al.
Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study
.
Int J Cardiol
.
2014
Jun
;
174
(
2
):
268
75
.
[PubMed]
0167-5273
18.
Bolger
AP
,
Bartlett
FR
,
Penston
HS
,
O’Leary
J
,
Pollock
N
,
Kaprielian
R
, et al.
Intravenous iron alone for the treatment of anemia in patients with chronic heart failure
.
J Am Coll Cardiol
.
2006
Sep
;
48
(
6
):
1225
7
.
[PubMed]
0735-1097
19.
Okonko
DO
,
Grzeslo
A
,
Witkowski
T
,
Mandal
AK
,
Slater
RM
,
Roughton
M
, et al.
Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial
.
J Am Coll Cardiol
.
2008
Jan
;
51
(
2
):
103
12
.
[PubMed]
0735-1097
20.
Anker
SD
,
Comin Colet
J
,
Filippatos
G
,
Willenheimer
R
,
Dickstein
K
,
Drexler
H
, et al.;
FAIR-HF Trial Investigators
.
Ferric carboxymaltose in patients with heart failure and iron deficiency
.
N Engl J Med
.
2009
Dec
;
361
(
25
):
2436
48
.
[PubMed]
0028-4793
21.
Ponikowski
P
,
van Veldhuisen
DJ
,
Comin-Colet
J
,
Ertl
G
,
Komajda
M
,
Mareev
V
, et al.;
CONFIRM-HF Investigators
.
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†
.
Eur Heart J
.
2015
Mar
;
36
(
11
):
657
68
.
[PubMed]
0195-668X
22.
Avni
T
,
Leibovici
L
,
Gafter-Gvili
A
.
Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis
.
Eur J Heart Fail
.
2012
Apr
;
14
(
4
):
423
9
.
[PubMed]
1388-9842
23.
Qian
C
,
Wei
B
,
Ding
J
,
Wu
H
,
Wang
Y
.
The Efficacy and Safety of Iron Supplementation in Patients With Heart Failure and Iron Deficiency: A Systematic Review and Meta-analysis
.
Can J Cardiol
.
2016
Feb
;
32
(
2
):
151
9
.
[PubMed]
0828-282X
24.
Anker
SD
,
Kirwan
BA
,
van Veldhuisen
DJ
,
Filippatos
G
,
Comin-Colet
J
,
Ruschitzka
F
, et al.
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis
.
Eur J Heart Fail
.
2018
Jan
;
20
(
1
):
125
33
.
[PubMed]
1388-9842
25.
Avni
T
,
Bieber
A
,
Grossman
A
,
Green
H
,
Leibovici
L
,
Gafter-Gvili
A
.
The safety of intravenous iron preparations: systematic review and meta-analysis
.
Mayo Clin Proc
.
2015
Jan
;
90
(
1
):
12
23
.
[PubMed]
0025-6196
26.
Hofmarcher
T
,
Cabrales Alin
D
,
Linde
C
.
Cost Effectiveness of Implementing ESC Guidelines for Treatment of Iron Deficiency in Heart Failure in the Nordic Countries
.
Scand Cardiovasc J SCJ
;
2018
. pp.
1
26
.
27.
Klip
IT
,
Comin-Colet
J
,
Voors
AA
,
Ponikowski
P
,
Enjuanes
C
,
Banasiak
W
, et al.
Iron deficiency in chronic heart failure: an international pooled analysis
.
Am Heart J
.
2013
Apr
;
165
(
4
):
575
582.e3
.
[PubMed]
0002-8703
28.
Comín-Colet
J
,
Enjuanes
C
,
González
G
,
Torrens
A
,
Cladellas
M
,
Meroño
O
, et al.
Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status
.
Eur J Heart Fail
.
2013
Oct
;
15
(
10
):
1164
72
.
[PubMed]
1388-9842
29.
Drozd
M
,
Jankowska
EA
,
Banasiak
W
,
Ponikowski
P
.
Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners
.
Am J Cardiovasc Drugs
.
2017
Jun
;
17
(
3
):
183
201
.
[PubMed]
1175-3277
30.
Vullaganti
S
,
Goldsmith
J
,
Teruya
S
,
Alvarez
J
,
Helmke
S
,
Maurer
MS
.
Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction
.
J Geriatr Cardiol
.
2014
Jun
;
11
(
2
):
100
5
.
[PubMed]
1671-5411
31.
Maurer
MS
,
Teruya
S
,
Chakraborty
B
,
Helmke
S
,
Mancini
D
.
Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy
.
Circ Heart Fail
.
2013
Mar
;
6
(
2
):
254
63
.
[PubMed]
1941-3289
32.
Kasner
M
,
Aleksandrov
AS
,
Westermann
D
,
Lassner
D
,
Gross
M
,
von Haehling
S
, et al.
Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction
.
Int J Cardiol
.
2013
Oct
;
168
(
5
):
4652
7
.
[PubMed]
0167-5273
33.
Sandek
A
,
Bjarnason
I
,
Volk
HD
,
Crane
R
,
Meddings
JB
,
Niebauer
J
, et al.
Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure
.
Int J Cardiol
.
2012
May
;
157
(
1
):
80
5
.
[PubMed]
0167-5273
34.
Lewis
GD
,
Malhotra
R
,
Hernandez
AF
,
McNulty
SE
,
Smith
A
,
Felker
GM
, et al.;
NHLBI Heart Failure Clinical Research Network
.
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial
.
JAMA
.
2017
May
;
317
(
19
):
1958
66
.
[PubMed]
0098-7484
35.
Macdougall
IC
,
Strauss
WE
,
McLaughlin
J
,
Li
Z
,
Dellanna
F
,
Hertel
J
.
A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD
.
Clin J Am Soc Nephrol
.
2014
Apr
;
9
(
4
):
705
12
.
[PubMed]
1555-9041
36.
Adkinson
NF
,
Strauss
WE
,
Macdougall
IC
,
Bernard
KE
,
Auerbach
M
,
Kaper
RF
, et al.
Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial
.
Am J Hematol
.
2018
May
;
93
(
5
):
683
90
.
[PubMed]
0361-8609
37.
Hetzel
D
,
Strauss
W
,
Bernard
K
,
Li
Z
,
Urboniene
A
,
Allen
LF
.
A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy
.
Am J Hematol
.
2014
Jun
;
89
(
6
):
646
50
.
[PubMed]
0361-8609
38.
Ponikowski
P
,
Voors
AA
,
Anker
SD
,
Bueno
H
,
Cleland
JG
,
Coats
AJ
, et al.;
ESC Scientific Document Group
.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
.
Eur Heart J
.
2016
Jul
;
37
(
27
):
2129
200
.
[PubMed]
0195-668X
39.
Yancy
CW
,
Jessup
M
,
Bozkurt
B
,
Butler
J
,
Casey
DE
 Jr
,
Colvin
MM
, et al.;
American College of Cardiology Foundation
.
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
.
J Am Coll Cardiol
.
2017
Aug
;
70
(
6
):
776
803
.
[PubMed]
0735-1097
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.